Targeted, localized drug delivery makes the difference
SINUVA treats recurring nasal polyps with targeted delivery of mometasone furoate directly to the tissue.
Coverage is better than everProven as safe and effective
Choose SINUVA—a localized drug delivery (LDD) solution that’s supported by the AAO and ARS. The International Forum of Allergy and Rhinology (IFAR) recommends SINUVA for treating recurrent nasal polyps. SINUVA targets nasal polyps directly with mometasone furoate so there’s negligible systemic impact, unlike other therapy alternatives.
Treatment with SINUVA involves a minimally invasive, in-office procedure that minimizes patient compliance, so they can get back to the things they love sooner.
Demonstrated efficacy for sustained relief
In clinical studies, SINUVA provided the relief patients need. It has been proven to provide effective relief, shrinking nasal polyps and reducing symptoms of nasal obstruction and congestion for up to 90 days. SINUVA patients experienced a 2.3X relative improvement in bilateral polyp grade (from baseline to Day 90).1,2,3
Download brochureDiscovering relief with SINUVA
Negligible systemic exposure
with localized delivery*
Little down time
with the SINUVA procedure
Fewer compliance issues
since the stent is placed and there’s nothing for patients to do or take
No needles
that patients need to be anxious about
*Mometasone furoate was not detected 14 days after placement of SINUVA in a pharmacokinetic study.
SINUVA has a proven safety profile*
Because SINUVA is placed directly amongst the nasal polyps, it is able to provide targeted symptom relief that is sustained up to 90 days, with a low rate of side effects.
SINUVA demonstrated similar local effects and hypersensitivity reactions compared to daily steroid nasal spray, with a low incidence of serious side effects.
See important safety information.
The rates of adverse reactions observed, were similar between SINUVA and patients treated with daily steroid nasal spray.
*The safety of SINUVA was established in 400 patients in 2 clinical trials.
Part of the IFAR treatment algorithm
The International Forum of Allergy and Rhinology (IFAR) has released its latest recommendation on the treatment of recurring nasal polyps. IFAR recommends SINUVA as an effective treatment for patients with recurring nasal polyps after ethmoid sinus surgery. SINUVA is the only steroid sinus implant approved for recurrent post-surgery polyp patients.
For physicians and patients who want to consider a non-surgical, localized treatment option for treating polyps, IFAR now recommends SINUVA. Watch the IFAR KOL video below.
More patients are covered than ever before4
Better coverage
More top insurance companies like United Healthcare, Aetna and Humana are now covering SINUVA, so more patients than ever can experience SINUVA relief. 82% of US patients are covered (over 78% of privately insured patients and over 90% of publicly insured patients).
Download payor coverage brochureQuick approval
It takes an average of 2 business days for SINUVA to be approved by insurance and an average of 10 business days after approval for SINUVA to be shipped—better than the industry average.*
*With payors that are on the SINUVA lives covered national list.
simplifies
approval process
Improved support
Medtronic’s CONNECT program is a reimbursement support program that helps simplify the patient enrollment, insurance approval, and acquisition processes for SINUVA. Your CONNECT case manager will guide you through it all.
Contact a reimbursement expertSign up to be contacted by a reimbursement expert
INDICATION
SINUVA Sinus Implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥ 18 years of age who have had ethmoid sinus surgery.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA Sinus Implant.
WARNINGS AND PRECAUTIONS
Local Nasal Adverse Reactions: Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.
Glaucoma and Cataracts: Nasal steroids may result in development of glaucoma and/or cataracts. Glaucoma, cataracts, and clinically significant elevation of intraocular pressure were not observed in patients from the treatment group of one randomized controlled clinical study (N = 53) who underwent bilateral placement of SINUVA Sinus Implants. Close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, angioedema have been reported with the use of corticosteroids.
Immunosuppression and Risk of Infections: Persons who are using drugs that suppress the immune system, such as corticosteroids, including SINUVA Sinus Implant are more susceptible to infections than healthy individuals. The safety and effectiveness of SINUVA Sinus Implant have not been established in pediatric patients less than 18 years of age and SINUVA is not indicated for use in this population. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
Hypercorticism and Adrenal Suppression: If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.
ADVERSE REACTIONS
The most common adverse reactions observed (> 1% of subjects) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.
POSTMARKETING EXPERIENCE
The following adverse reactions have been identified during post-approval use of the SINUVA sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.
Rx only. Please see Full Prescribing Information. for SINUVA.
Indication and Important Safety Information!!!
See MoreINDICATION
SINUVA Sinus Implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥ 18 years of age who have had ethmoid sinus surgery.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA Sinus Implant.
WARNINGS AND PRECAUTIONS
Local Nasal Adverse Reactions: Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.
Glaucoma and Cataracts: Nasal steroids may result in development of glaucoma and/or cataracts. Glaucoma, cataracts, and clinically significant elevation of intraocular pressure were not observed in patients from the treatment group of one randomized controlled clinical study (N = 53) who underwent bilateral placement of SINUVA Sinus Implants. Close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, angioedema have been reported with the use of corticosteroids.
Immunosuppression and Risk of Infections: Persons who are using drugs that suppress the immune system, such as corticosteroids, including SINUVA Sinus Implant are more susceptible to infections than healthy individuals. The safety and effectiveness of SINUVA Sinus Implant have not been established in pediatric patients less than 18 years of age and SINUVA is not indicated for use in this population. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
Hypercorticism and Adrenal Suppression: If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.
ADVERSE REACTIONS
The most common adverse reactions observed (> 1% of subjects) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.
POSTMARKETING EXPERIENCE
The following adverse reactions have been identified during post-approval use of the SINUVA sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.
Rx only. Please see Full Prescribing Information. for SINUVA.
- SINUVA [Prescribing Information]. Menlo Park, CA: Intersect ENT; 2023.
- Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol. 2018;8(4):471-481.
- Data on file, Intersect ENT, Inc. CR-00014; Supplemental Statistical Analyses Rev 1.0 January 17, 2018.
- SINUVA Market Access Enrollments. Medtronic data on file. 2022.